Fesoterodine fumarate

CAS No. 286930-03-8

Fesoterodine fumarate( PF-00695838 fumarate )

Catalog No. M13874 CAS No. 286930-03-8

Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 50 In Stock
10MG 80 In Stock
25MG 129 In Stock
50MG 178 In Stock
100MG 266 In Stock
500MG 511 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fesoterodine fumarate
  • Note
    Research use only, not for human use.
  • Brief Description
    Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties.
  • Description
    Fesoterodine (PF-00695838) is a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties; binds and inhibits muscarinic receptors on the bladder detrusor muscle, prevents bladder contractions or spasms caused by acetylcholine.Other Indication Approved(In Vitro):FFesoterodine Fumarate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.After oral administration, Fesoterodine Fumarate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).(In Vivo):Fesoterodine Fumarate (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg.
  • In Vitro
    FFesoterodine Fumarate decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition.After oral administration, Fesoterodine Fumarate is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine).
  • In Vivo
    Fesoterodine Fumarate (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg. Animal Model:Bladders from female Sprague-Dawley rats (225-275 g)Dosage:0.01, 0.1 and 1 mg/kg Administration:IV Result:Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg.
  • Synonyms
    PF-00695838 fumarate
  • Pathway
    GPCR/G Protein
  • Target
    mAChR
  • Recptor
    mAChR
  • Research Area
    Other Indications
  • Indication
    Other Disease

Chemical Information

  • CAS Number
    286930-03-8
  • Formula Weight
    527.658
  • Molecular Formula
    C30H41NO7
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 93 mg/mL (176.3 mM); Ethanol: 93 mg/mL (176.3 mM); Water: 92 mg/mL (174.4 mM) ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O
  • Chemical Name
    [2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate fumarate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ney P, et al. BJU Int. 2008 Apr;101(8):1036-42. 2. Michel MC. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. 3. Chapple CR, et al. BJU Int. 2008 Nov;102(9):1128-32.
molnova catalog
related products
  • Batefenterol

    A bifunctional M3 mAChR antagonist and β2-adrenoceptor agonist (MABA) with pKi/pEC50 of 8.7/9.6 for hM3/hβ2 respectively.

  • Biperiden

    Biperiden (KL 373) is a centrally-acting antiparkinsonian agent that functions as a selective central M1 cholinoreceptors blocker.

  • TAK-071

    TAK-071 (TAK071) is a novel potent, selective, low cooperativity (α-value) positive allosteric modulator of muscarinic M1 receptor with inflection point of 2.7 nM in Ca2+ flux assays in CHO-K1 cells.